Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin resistance in type 2 diabetes: myocardial mechanisms and effects of GLP-1RA and SGLT2 inhibitor therapy
2025-523374-17-03Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of semaglutide and dapagliflozin in type 2 diabetes mellitus (T2DM) and myocardial insulin resistance, sponsored by Vall d'Hebron Research Institute. Primary endpoint: Myocardium insulin resistance. Planned start Oct 2026; status: authorised.
02
Drugs
semaglutidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)myocardial insulin resistance
Beyond the preview
Go deeper on 2025-523374-17-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523374-17-03.